Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, First-in-Human, Open-Label, Dose Escalation Study of Duvortuxizumab, A Humanized CD19 x CD3 Dual-Affinity Re-Targeting (DART®) Protein in Subjects With Relapsed or Refractory B-cell Malignancies

NCT02454270 is registered in ClinicalTrials.gov with Janssen Research & Development, LLC as lead sponsor.

NCT NCT02454270
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02454270 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, First-in-Human, Open-Label, Dose Escalation Study of Duvortuxizumab, A Humanized CD19 x CD3 Dual-Affinity Re-Targeting (DART®) Protein in Subjects With Relapsed or Refractory B-cell Malignancies
Lead sponsor
Janssen Research & Development, LLC
Phase
Phase 1
Overall status
Terminated
Start date
June 15, 2015
Completion date
July 26, 2018
Enrollment
59 (actual)
Sites
20

Conditions

As the registry lists them; a condition with its own page is linked.

leukemia, lymphocytic, chronic, b-cell, lymphoma, follicular, lymphoma, large b-cell, diffuse, lymphoma, mantle-cell, precursor cell lymphoblastic leukemia-lymphoma